HELLP syndrome: Difference between revisions

(Text replacement - " ==" to "==")
No edit summary
(9 intermediate revisions by 5 users not shown)
Line 1: Line 1:
==Background==
==Background==
*HELLP = Hemolysis, Elevated LFTS, Low Platelets
*HELLP = [[hemolytic anemia|Hemolysis]], Elevated [[LFTs]], [[thrombocytopenia|Low Platelets]]
*Clinical variant of preeclampsia
*Clinical variant of [[preeclampsia]]
*Any patient >20wk gestation or <4wk postpartum c/o abd pain should receive HELLP w/u
*Any patient >20wk gestation or <4wk postpartum complaining of abdominal pain should receive HELLP workup
*Usually presents w/in 48 hr of delivery
*When occurring postpartum, typically presents within 48hr of delivery
*80% of patients have no evidence of preeclampsia before delivery
*80% of patients have no evidence of preeclampsia before delivery


==Clinical Features==
==Clinical Features==
*RUQ or epigastric pain - 40-90%
*[[RUQ pain|RUQ]] or [[epigastric pain]] (40-90%)
*Proteinuria - 86-100%
*[[Proteinuria]] (86-100%)
*Hypertension - 82-88%
*[[Hypertension]] (82-88%)
 
===Complications===
*[[Disseminated intravascular coagulation]]
*[[Acute kidney injury]]
*Subcapsular liver hematoma
*[[Hemorrhage]]


==Differential Diagnosis==
==Differential Diagnosis==
Line 19: Line 25:
Evaluation is targeted at assessing the individual components of the syndrome. Labs to be drawn should include a:
Evaluation is targeted at assessing the individual components of the syndrome. Labs to be drawn should include a:
*CBC  
*CBC  
**May see a microangiopathic hemolytic anemia (Schistocytes on microscopy)
**May see a [[microangiopathic hemolytic anemia]] (Schistocytes on microscopy)
**Platelet count <100/µL
**[[thrombocytopenia|Platelet count <150]] × 10<sup>9</sup> per L (150 per mm<sup>3</sup>)
*Chemistry
*Chemistry
**Normal or elevated BUN/Cr
**Normal or elevated BUN/Cr
*Coagulation panel
*Coagulation panel (fibrinogen can be decreased and PTT elevated)
**Abnormalities only if there is component of [[DIC]]
**Patients can progress towards [[DIC]]
*LFT
*[[LFTs]]
**AST > 70 U/L, bilirubin > 1.2 mg/dL
**AST levels > 150 IU/L and ALT levels > 100 IU/L (also often associated with bilirubin > 1.2mg/dL
**ALT elevation (although usually <500)
**LDH elevation (often > 600 IU/L)
*LDH > 600 IU/L
*[[UA]] ([[proteinuria]])
*CT or US can be considered if there is pain requiring a greater workup.
*CT or [[Ultrasound (main)|ultrasound]] can be considered if there is pain requiring a greater workup.
**Patients depending on degree of thrombocytopenia are at risk of developming intraabdominal bleeding such as a hepatic hematoma
**Depending on degree of [[thrombocytopenia]] are at risk for developing intraabdominal bleeding such as a hepatic hematoma


==Treatment==
==Management==
*Similar to that of severe [[preeclampsia]] or [[eclampsia]]
*Similar to that of severe [[preeclampsia]] or [[eclampsia]]
**Delivery (only definitive treatment)
**Delivery (only definitive treatment)
**[[Magnesium]]
**[[Magnesium sulfate]]
**BP control
**[[antihypertensives|BP control]]
**[[Coagulopathy correction]]
**[[Coagulopathy (main)|Coagulopathy correction]]
***Transfuse [[platelets]] if < 20,000 or active, uncontrolled bleeding
***Transfuse [[platelets]] if < 20,000 or active, uncontrolled bleeding


==Complications==
==Disposition==
*[[DIC]]
*Admit
*[[Acute renal failure]]
*Subcapsular liver hematoma
*Hemorrhage


==See Also==
==See Also==
Line 50: Line 53:


==References==
==References==
*EBM, Volume 12, Number 8, Aug 2010. Postpartum Emergencies
<references/>


[[Category:OBGYN]]
[[Category:OBGYN]]

Revision as of 17:40, 16 October 2019

Background

  • HELLP = Hemolysis, Elevated LFTs, Low Platelets
  • Clinical variant of preeclampsia
  • Any patient >20wk gestation or <4wk postpartum complaining of abdominal pain should receive HELLP workup
  • When occurring postpartum, typically presents within 48hr of delivery
  • 80% of patients have no evidence of preeclampsia before delivery

Clinical Features

Complications

Differential Diagnosis

3rd Trimester/Postpartum Emergencies

Microangiopathic Hemolytic Anemia (MAHA)

Evaluation

Evaluation is targeted at assessing the individual components of the syndrome. Labs to be drawn should include a:

  • CBC
  • Chemistry
    • Normal or elevated BUN/Cr
  • Coagulation panel (fibrinogen can be decreased and PTT elevated)
    • Patients can progress towards DIC
  • LFTs
    • AST levels > 150 IU/L and ALT levels > 100 IU/L (also often associated with bilirubin > 1.2mg/dL
    • LDH elevation (often > 600 IU/L)
  • UA (proteinuria)
  • CT or ultrasound can be considered if there is pain requiring a greater workup.
    • Depending on degree of thrombocytopenia are at risk for developing intraabdominal bleeding such as a hepatic hematoma

Management

Disposition

  • Admit

See Also

References